Clinical Trials Browser

Phase 3 × luspatercept × 90 days × Clear all

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia